Sacubitril/valsartan (Entresto®) granted expanded indication in chronic heart failure by FDA

FDA approved Entresto to treat patients diagnosed with heart failure with reduced ejection fraction (HFrEF) and with heart failure with preserved ejection fraction (HFpEF). Approval is based on Phase III active-controlled PARAGON-HF study.

Source:

Biospace Inc.